PAK6 and Parkinson disease: Of note, patients affected by sporadic and G2019S LRRK2-linked PD exhibit changes in the amount of circulating PAK6 and of its substrate and LRRK2 interactor 14–3–3γ [37], highlighting the potential clinical relevance of this pathway.